Navigation Links
Cognizant to Deliver Comprehensive Biostatistics and Medical Reporting Services for AstraZeneca
Date:11/30/2011

LONDON, Nov. 30, 2011 /PRNewswire/ -- Cognizant (NASDAQ: CTSH), a leading provider of consulting, technology, and business process outsourcing services, today announced a multi-year agreement with AstraZeneca to deliver comprehensive biostatistics and medical reporting services to generate clinical study reports.

Under the agreement, Cognizant will provide centralized statistical programming, statistical analysis, medical writing, and document publishing services, spanning the entire chain of clinical data reporting from case report forms to clinical study reports. This will enable AstraZeneca to increase operational efficiency, reduce cycle times, and optimize costs. AstraZeneca will continue to own and manage key scientific and medical activities associated with the design of clinical trial programs, and the interpretation of data from them.

Cognizant will leverage its proprietary Web 2.0-based platform, Cognizant 2.0, to support knowledge sharing and collaboration across global teams, allowing clinical studies across different countries to be managed simultaneously, and delivering significant productivity benefits to AstraZeneca.

"Cognizant will help us streamline our clinical development operations. This is key to our business transformation aimed at achieving greater efficiency, agility, flexibility, and global competitiveness -- all of which are crucial to clinical trials and development of new drugs," said Karin Wingstrand, Vice President and Head of Clinical Development at AstraZeneca. "Leveraging Cognizant's IT and business process expertise allows AstraZeneca to focus more time, energy, and investment on those clinical activities that will make a difference in developing innovative medicines more quickly for patients."

"We are pleased to have been selected by AstraZeneca to provide biostatistics and medi
'/>"/>

SOURCE Cognizant
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance
2. Virtual Childbirth Simulator Improves Safety of High-Risk Deliveries
3. Delivering Exceptional Medical Science Liaison Services to Key Stakeholders in the Marketplace
4. Philips CT iDose4 Iterative Reconstruction Technique Advances Patient Care by Delivering Improved Image Quality at Low Dose
5. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
6. Tandem Diabetes Care Announces FDA Clearance of the t:slim™ Insulin Delivery System
7. BioDelivery Sciences to Host Business Update Webcast and Conference Call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time
8. Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges
9. BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
10. IDEV Technologies Receives FDA Clearance for Its SUPERA VERITAS® 6 French Stent Delivery System
11. Everist Genomics to Launch CardioDefender: Worlds Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... DIEGO, July 31, 2014 Tandem Diabetes Care®, Inc. ... manufacturer of the t:slim® Insulin Pump, today reported its financial ... In comparing the second quarter of 2014 to the ... to $10.3 million from $5.5 million , t:slim Pump ... In comparing six months ended June 30, 2014 ...
(Date:7/31/2014)... SAN FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... the second quarter ended June 30, 2014. ... were $301.4 million as compared to $309.1 million at March ... time for Nektar as we look forward to significant milestones ... W. Robin, President and Chief Executive Officer of Nektar. "The ...
(Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... International Workshop on Hepatitis C ... Resistance & New ... today presented data on novel Hepatitis C protease,inhibitors with potent ... properties with the potential,for once-daily dosing in humans. The ...
... Partnership Valued up to $18 Million over Five ... 31 ,The U.S. President,s Emergency Plan for AIDS ... to announce the signing of a,Memorandum of Understanding ... laboratory systems and services in African countries,severely affected ...
Cached Medicine Technology:Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies 2BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB 2BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB 3BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB 4
(Date:8/1/2014)... aesthetic injectable procedures have grown in popularity as more ... As Botulinum toxin generally known as BOTOX ... health professionals have emerged to perform procedures utilizing this ... Spinelli, MD from the Division of Plastic Surgery Presbyterian ... from Columbia University in New York have assessed the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 With fast food ... and the convenience of processed, microwavable dinners, it is no ... does not offer patients a mere quick fix for shedding ... in any part of the country, get slimmer and healthier ... offer patients the tools and education on how to ...
(Date:8/1/2014)... August 01, 2014 St. Christopher's Hospital ... an upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , St. Christopher's Hospital for ... for children from birth through 21 years of age. ... of the hospital's specialties, including autism and childhood obesity. ...
(Date:8/1/2014)... 01, 2014 For many people, forgetfulness ... is still within the normal range, slips that seem ... future decline. This merits a closer look, not a ... 2014 Harvard Men's Health Watch . , ... forget where their keys are they are on the ...
(Date:8/1/2014)... 2014 Narconon Arrowhead recently celebrated the ... the drug rehab center located in the small town ... Arrowhead is the flagship drug rehab center in the ... States for services there. Now, with such a long ... studies as well as client reviews showing the effectiveness ...
Breaking Medicine News(10 mins):Health News:Plastic surgeons or nurses: Who are the better injectors? 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Worried About Changes in Your Memory? It's Worth A Closer Look, From the August 2014 Harvard Men's Health Watch 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3
... spike between 2008 and 2009, analysis finds , SATURDAY, ... appear to be on the rise, warns the American ... and baseball/softball are the main culprits. , The cautionary ... as they transpired between 2008 and 2009, based on ...
... drinkers were 39% less likely to get these malignancies ... help protect against head and neck cancers, a new ... the International Head and Neck Cancer Epidemiology consortium. They ... a day) were 39 percent less likely to develop ...
... is part of being a good dad, expert suggests , ... dads unwrap their new ties and other tokens of gratitude, ... kind of gift: a promise that they,ll watch their health, ... On average, men die younger than women and are more ...
... radiation not always ideal for many with low risk ... -- For patients with prostate cancer that has a ... "watchful waiting," may be a suitable treatment option, according ... of how (or whether) to treat localized prostate cancer ...
... ... ... Technologies , the leading independent provider of search software integration services announced today an ... for the Folio and NXT professional publishing products. The Folio product family includes Folio ...
... Recent research has shown increase in sexual satisfaction, if ... A U.S. Food and Drug Administration advisory panel on ... the "female Viagra" for premenopausal women with a diminished ... to the antidepressant family and affects serotonin and other ...
Cached Medicine News:Health News:Bump in Head Injury Numbers Linked to Summer Play 2Health News:On Father's Day, Give Dad Gift of Health 2Health News:'Watchful Waiting' Often Best Strategy for Slow-Moving Prostate Cancer 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 2Health News:Search Technologies Partners with Rocket Software to Provide Expert Support for Folio and NXT Products 3
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
... NMP22® Test Kit is a quantitative microplate enzyme ... are at risk for rapid recurrence or occult ... voided urine sample and is twice as sensitive ... to improve patient outcome by identifying those patients ...
... Unlike other ESR products, SEDIPLAST® ... superior design features to protect laboratory ... blood handling. SEDIPLAST® is a uniquely ... which provides greater safety and convenience ...
Medicine Products: